Covid-19 has plunged antibody drug development into the spotlight. But antibodies are not a new area of pharma R&D. To find out more, we take a look at the history of antibodies as a therapy model, and as the FDA resumes manufacturing inspections, we get insider insight into the inspection process.
Also, we examine the therapeutic properties of the ‘love hormone’ oxytocin, find out how AI-enabled risk detection is helping to finesse the pharmaceutical supply chain, and explore the potential long-term health impacts of Covid-19 and the therapies that may be needed to treat them in the future.
Plus, we review the progress of Janssen’s investigational gene therapy for inherited X-linked retinitis pigmentosa, learn about the growth of the fertility drug investment landscape, and explore novel drug treatments targeting coeliac disease that could improve symptom control and quality of life for coeliac patients.
Editor | Eloise McLennan
Group Editor | Susanne Hauner
Commissioning Editor | Daniel Garrun
Writers | Allie Nawrat, Chris Lo, Abi Millar, Natalie Healey, Chloe Kent, Xavier Duburcq, Romuald Braun
Magazine Designer | Marzia Del Gaone
Graphic Designers | Filipe Costa, Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Martina Labaiova
Lead Designer | John Hammond
Digital Publishing Director | Duncan West
Sales Manager | Nimai Amin
+44 (0) 207 936 6453
For media partnership enquiries please contact: Susanne Hauner
Pharma Technology focus is powered by h5mag
read past issues of pharma technology focus HERE
Copyright 2020 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.